Biomarin Pharmaceutical Inc. (NASDAQ: BMRN)’s Stock Performance and Outlook

In the last trading session, 2.03 million Biomarin Pharmaceutical Inc. (NASDAQ:BMRN) shares changed hands as the company’s beta touched 0.32. With the company’s per share price at $75.52 changed hands at -$0.38 or -0.50% during last session, the market valuation stood at $14.34B. BMRN’s last price was a discount, traded about -31.83% off its 52-week high of $99.56. The share price had its 52-week low at $75.03, which suggests the last value was 0.65% up since then. When we look at Biomarin Pharmaceutical Inc.’s average trading volume, we note the 3-month average coming to 1.64 million.

Biomarin Pharmaceutical Inc. (NASDAQ:BMRN) trade information

Instantly BMRN was in red as seen at the end of in last trading. With action -2.63%, the performance over the past five days has been red. The drop to weekly highs of 78.19 subtracted -0.50% to the stock’s daily price. The company’s shares are showing year-to-date downside of -21.68%, with the 5-day performance at -2.63% in the red. However, in the 30-day time frame, Biomarin Pharmaceutical Inc. (NASDAQ:BMRN) is -8.09% down.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Biomarin Pharmaceutical Inc. (BMRN) estimates and forecasts

Data shows that the Biomarin Pharmaceutical Inc. share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -14.59% over the past 6 months, a 37.50% in annual growth rate that is considerably higher than the industry average of 15.30%. Year-over-year growth is forecast to reach 13.40% up from the last financial year.

Consensus estimates given by 22 financial analysts project the company’s revenue in the current quarter to hit an average of 660.76M. 22 analysts are of the opinion that Biomarin Pharmaceutical Inc.’s revenue for the current quarter will be 691.47M. The estimates for the next quarter sales put growth at 13.60%.

The 2024 estimates are for Biomarin Pharmaceutical Inc. earnings to increase by 98.28%, but the outlook for the next 5-year period is at 43.00% per year.

BMRN Dividends

Biomarin Pharmaceutical Inc. is expected to release its next quarterly earnings report in June.